Peptide profile
ARA-290 (Cibinetide)
Erythropoietin analog for kidney protection
Compare ARA-290 (Cibinetide) with other peptides →Summary
A tiny protein that helps protect your kidneys and nerves.
- Typical dose
- 0.5-1.0mg Daily
- Route
- Subcutaneous
- Cycle length
- 30-90 days
- Evidence
- Animal data
Mechanism
How it works
ARA-290 works like a 'repair only' version of EPO — it tells kidneys and nerves to heal without increasing red blood cell production.
ARA-290 is a non-erythropoietic EPO derivative that activates the EPO receptor's tissue-protective (not erythropoietic) pathway, reducing inflammation and fibrosis.
Reported in research
Benefits
- Helps your kidneys work well
- Stops scar tissue from building up in kidneys
- Helps nerves work better (for people with diabetes)
- Calms swelling without making more blood cells
Context, not a prescription
Dosing
- Typical range
- 0.5-1.0mg Daily (Subcutaneous)
- Cycle length
- 30-90 days
Safety
Side effects & contraindications
Possible side effects
- Injection site pain
- Mild headache
- Fatigue
- Nausea
- Dizziness
Contraindications
- Pregnancy or breastfeeding
- Polycythemia (theoretical risk)
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Less kidney scarring, better kidney work, and less nerve pain.
How it works
ARA-290 is like a 'repair only' version of EPO. It tells your kidneys and nerves to heal. But it does not make more red blood cells.
It connects to the same spot as EPO. But it sends a different message that calms swelling.
What to expect
It protects your body slowly, over weeks to months.
- Weeks 2-4: Less swelling inside the body.
- Weeks 4-8: Kidneys start working better.
- Weeks 8-12: Less nerve pain.
Good to know
- Start with a smaller dose
- Check your blood counts (no change is expected)
Staying safe
- Sore spot where you got the shot
- Mild headache
- Feeling tired
Avoid if you have:
- People who are pregnant or breastfeeding
- People with too many red blood cells (just to be safe)
Mechanism of action
ARA-290 is a non-erythropoietic EPO derivative that activates the EPO receptor's tissue-protective (not erythropoietic) pathway, reducing inflammation and fibrosis.
Binds to EPO receptor homodimer but signals through different pathways (JAK2/STAT vs anti-inflammatory).
Pharmacodynamics
Protective effects over weeks to months.
Reduced kidney fibrosis, improved renal function, less neuropathic pain.
Timeline
- Weeks 2-4: Reduced inflammatory markers.
- Weeks 4-8: Improved kidney function markers.
- Weeks 8-12: Reduced neuropathic pain.
Comparisons
- ARA-290 — effectiveness Emerging, safety Good, cost $$$, Medium to use
- ACE Inhibitors — effectiveness High, safety Good, cost $, Easy to use
Adverse effects
Common:
- Injection site pain
- Mild headache
- Fatigue
Rare:
- Nausea
- Dizziness
Contraindications & risk mitigation
Contraindicated in:
- Pregnancy or breastfeeding
- Polycythemia (theoretical risk)
- Start with lower dose
- Monitor blood counts (no expected effect)
Qué hace
Menos cicatrices en los riñones, mejor funcionamiento renal y menos dolor nervioso.
Cómo funciona
ARA-290 es como una versión de 'solo reparación' de la EPO. Le indica a tus riñones y nervios que se curen. Pero no produce más glóbulos rojos.
Se conecta al mismo lugar que la EPO. Pero envía un mensaje diferente que calma la inflamación.
Qué esperar
Protege tu cuerpo lentamente, a lo largo de semanas a meses.
- Semanas 2-4: Menos inflamación interna.
- Semanas 4-8: Los riñones comienzan a funcionar mejor.
- Semanas 8-12: Menos dolor nervioso.
Bueno saber
- Comenzar con una dosis más pequeña
- Revisar tus análisis de sangre (no se espera cambio)
Manteniéndose seguro
- Zona dolorosa donde te aplicaste la inyección
- Dolor de cabeza leve
- Sensación de cansancio
Evitar si tienes:
- Personas que están embarazadas o en periodo de lactancia
- Personas con demasiados glóbulos rojos (solo por precaución)
Mecanismo de acción
ARA-290 es un derivado no eritropoyético de la EPO que activa la vía protectora de tejidos (no eritropoyética) del receptor de EPO, reduciendo la inflamación y la fibrosis.
Se une al homodímero del receptor de EPO pero activa vías de señalización diferentes (JAK2/STAT frente a antiinflamatorias).
Farmacodinamia
Efectos protectores a lo largo de semanas a meses.
Reducción de la fibrosis renal, mejora de la función renal, menor dolor neuropático.
Cronología
- Semanas 2-4: Reducción de marcadores inflamatorios.
- Semanas 4-8: Mejora de los marcadores de función renal.
- Semanas 8-12: Reducción del dolor neuropático.
Comparaciones
- ARA-290 — efectividad Emergente, seguridad Buena, costo $$$, Media de usar
- Inhibidores de la ECA — efectividad Alta, seguridad Buena, costo $, Fácil de usar
Efectos adversos
Comunes:
- Dolor en el sitio de inyección
- Dolor de cabeza leve
- Fatiga
Raros:
- Náuseas
- Mareos
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Embarazo o lactancia
- Policitemia (riesgo teórico)
- Comenzar con una dosis menor
- Monitorear recuento sanguíneo (no se espera efecto)
Reference data
Specifications
- Route
- Subcutaneous
- Cycle length
- 30-90 days
FAQ
Common questions
Does ARA-290 increase red blood cells?
No, it is specifically designed to be non-erythropoietic while retaining tissue-protective effects.
Is it approved for human use?
No, it is investigational; Phase II trials for sarcoidosis and diabetic neuropathy.
What is the evidence level?
This compound is classified as Animal data. Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Research
Research & sources
Current evidence for ARA-290 (Cibinetide) is rated as Animal data. Research is based primarily on animal models.
- 1. ARA-290 in diabetic nephropathy (2016) — DOI:10.2337/db15-0957
- 2. Non-erythropoietic EPO peptides (2010) — DOI:10.1038/nrneph.2010.86
- 3. ARA-290 in diabetic nephropathy (2016)
- 4. Non-erythropoietic EPO peptides (2010)